{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T01:18:16Z","timestamp":1778635096314,"version":"3.51.4"},"reference-count":191,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2012,8,30]],"date-time":"2012-08-30T00:00:00Z","timestamp":1346284800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Reviews in Medical Virology"],"published-print":{"date-parts":[[2012,11]]},"abstract":"<jats:title>SUMMARY<\/jats:title><jats:p>After a decade of having been the standard of care (SOC) for the treatment of chronic HCV infection, PEGylated IFN (combined with ribavirin) is now at the verge of being complemented and then replaced by a combination of new DAAs and even some compounds interacting with host cell factors. Principal targets for the direct\u2010acting antivirals (DAAs) are the protease NS3\/4A, the protein NS5A, and the RNA\u2010dependent RNA polymerase NS5B, which offers at least two target sites, the catalytic domain for nucleos(t)ides and several non\u2010catalytic (allosteric) domains for the non\u2010nucleoside type of NS5B inhibitors. Two PIs have already been approved, but many more NS3\/4A, NS5A, and NS5B (up to 40!) inhibitors are in (pre)clinical development. The abundance of candidate anti\u2010HCV drugs will, on the one hand, speed up their development but, on the other hand, complicate the choice of the most appropriate drug combination(s). Copyright \u00a9 2012 John Wiley &amp; Sons, Ltd.<\/jats:p>","DOI":"10.1002\/rmv.1727","type":"journal-article","created":{"date-parts":[[2012,8,31]],"date-time":"2012-08-31T03:43:59Z","timestamp":1346384639000},"page":"392-411","source":"Crossref","is-referenced-by-count":17,"title":["The race for interferon\u2010free HCV therapies: a snapshot by the spring of 2012"],"prefix":"10.1002","volume":"22","author":[{"given":"Erik","family":"De Clercq","sequence":"first","affiliation":[{"name":"Rega Institute for Medical Research KU Leuven  Leuven Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,8,30]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/474S2a"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/474S5a"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr215"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06102-5"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020047"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808010"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir076"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-147-10-200711200-00003"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.07.009"},{"key":"e_1_2_13_11_1","first-page":"647","article-title":"UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients","volume":"35","author":"Ramachandran P","year":"2012","journal-title":""},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2011.02715.x"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3361"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3623"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(12)60010-5"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2011.02705.x"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.10.020"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm201384j"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2011.02699.x"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.04.015"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2011.01526.x"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2210-7401(11)70009-2"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2210-7401(11)70008-0"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0806104"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908014"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1012912"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1013086"},{"issue":"1","key":"e_1_2_13_28_1","first-page":"abstract 52","article-title":"Telaprevir in combination with peginterferon alfa 2A and ribavirin increased sustained virologic response rates in genotype 1 HCV patients compared with peginterferon\/ribavirin. HEP DART 2011, Kauai, Hawaii, 4\u20138 December 2011","volume":"7","author":"Kauffman RS","year":"2011","journal-title":"Global Antiviral Journal"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1010494"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009482"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2011.02700.x"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2011.02718.x"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2011.02702.x"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25653"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2011.01528.x"},{"key":"e_1_2_13_36_1","first-page":"469","article-title":"Diagnosis and management of telaprevir\u2010associated rash","volume":"7","author":"Lawitz EJ","year":"2011","journal-title":"Gastroenterolog\u00eda y Hepatolog\u00eda"},{"key":"e_1_2_13_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25574"},{"key":"e_1_2_13_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr581"},{"key":"e_1_2_13_39_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05184-11"},{"key":"e_1_2_13_40_1","unstructured":"http:\/\/www.aidsbeacon.com\/news\/2011\/04\/29\/new\u2010drugs\u2010for\u2010hepatitis\u2010c\u2010part\u20101\u2010boceprevir\u2010and\u2010telaprevir\u2010provide\u2010higher\u2010cure\u2010rates\/"},{"key":"e_1_2_13_41_1","unstructured":"http:\/\/www.aidsbeacon.com\/news\/2011\/04\/30\/new\u2010drugs\u2010for\u2010hepatitis\u2010c\u2010part\u20102\u2010boceprevir\u2010and\u2010telaprevir\u2010dosing\u2010regimens\u2010and\u2010side\u2010effects\/"},{"key":"e_1_2_13_42_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.06.004"},{"key":"e_1_2_13_43_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00777-10"},{"key":"e_1_2_13_44_1","unstructured":"http:\/\/insciences.org\/article.php?article_id=9618"},{"key":"e_1_2_13_45_1","unstructured":"http:\/\/www.hivandhepatitis.com\/2011_conference\/easl2011\/docs\/0426_2010_a.html"},{"key":"e_1_2_13_46_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm100690x"},{"key":"e_1_2_13_47_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00787-10"},{"key":"e_1_2_13_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.08.040"},{"key":"e_1_2_13_49_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05166-11"},{"key":"e_1_2_13_50_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.211417"},{"key":"e_1_2_13_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(10)60763-5"},{"key":"e_1_2_13_52_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05854-11"},{"key":"e_1_2_13_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2012.01.017"},{"key":"e_1_2_13_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2011.12.038"},{"key":"e_1_2_13_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.11.001"},{"key":"e_1_2_13_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.01.046"},{"key":"e_1_2_13_57_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir315"},{"key":"e_1_2_13_58_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00131-11"},{"key":"e_1_2_13_59_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2010.219089"},{"key":"e_1_2_13_60_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24172"},{"key":"e_1_2_13_61_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05636-11"},{"key":"e_1_2_13_62_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm9015526"},{"key":"e_1_2_13_63_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00677-09"},{"issue":"1","key":"e_1_2_13_64_1","first-page":"abstract 48","article-title":"Safety and antiviral activity of MK\u20105172, a next generation HCV NS3\/4A protease inhibitor with a broad HCV genotypic activity spectrum and potent activity against known resistance mutants, in genotype\u20101 and \u20103 HCV\u2010infected patients. HEP DART 2011, Kauai, Hawaii, 4\u20138 December 2011","volume":"7","author":"Fraser IP","year":"2011","journal-title":"Global Antiviral Journal"},{"key":"e_1_2_13_65_1","unstructured":"LalezariJ HazanL KankamM et al.High rapid virologic response (RVR) with ACH\u20101625 daily dosing plus pegIFN\u2010alpha 2a\/RBV in a 28\u2010day phase 2a trial. Abstracts of the 62th Annual Meeting of the American Association for the Study of Liver Diseases San Francisco CA 6\u20139 November2011."},{"key":"e_1_2_13_66_1","unstructured":"http:\/\/hcvadvocate.blogspot.com\/2012\/01\/ach\u20101625\u2010receives\u2010fast\u2010track.html"},{"key":"e_1_2_13_67_1","unstructured":"http:\/\/www.achillion.com\/ACH_2684"},{"key":"e_1_2_13_68_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00135-10"},{"key":"e_1_2_13_69_1","doi-asserted-by":"publisher","DOI":"10.2174\/138620712800563918"},{"key":"e_1_2_13_70_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23899"},{"key":"e_1_2_13_71_1","doi-asserted-by":"publisher","DOI":"10.1002\/anie.200906696"},{"key":"e_1_2_13_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2008.07.088"},{"key":"e_1_2_13_73_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01058-08"},{"key":"e_1_2_13_74_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01452-09"},{"key":"e_1_2_13_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2011.11.007"},{"key":"e_1_2_13_76_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.10.033"},{"key":"e_1_2_13_77_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1894"},{"key":"e_1_2_13_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.12.033"},{"key":"e_1_2_13_79_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature08960"},{"key":"e_1_2_13_80_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25581"},{"key":"e_1_2_13_81_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00556-10"},{"key":"e_1_2_13_82_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05977-11"},{"key":"e_1_2_13_83_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06169-11"},{"key":"e_1_2_13_84_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24609"},{"key":"e_1_2_13_85_1","doi-asserted-by":"crossref","unstructured":"PolS GhalibRH RustgiVK et al.First report of SVR12 for a NS5A replication complex inhibitor BMS\u2010790052 in combination with peg\u2010IFN\u2010\u03b1\u20102a and RBV: phase 2A trial in treatment\u2010na\u00efve HCV\u2010genotype 1 subjects. Poster presentations of the International Liver Congress 2011\u2014the 46th Annual Meeting of the European Association for the Study of the Liver (EASL) Berlin Germany 30 March\u20133 April2011.","DOI":"10.1016\/S0168-8278(11)61375-5"},{"key":"e_1_2_13_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.12.029"},{"key":"e_1_2_13_87_1","doi-asserted-by":"crossref","unstructured":"SulkowskiM Rodriguez\u2010TorresM LawitzE et al.Interim sustained virologic response rates in treatment\u2010na\u00efve HCV genotype 1a and 1b patients treated for 12 or 24\u2009weeks with an interferon\u2010free all\u2010oral quad regimen. Latebreaker poster presentations of the International Liver Congress 2012\u2014the 47th Annual Meeting of the European Association for the Study of the Liver (EASL) Barcelona Spain 18\u201322 April2012 #1421.","DOI":"10.1016\/S0168-8278(12)61432-9"},{"key":"e_1_2_13_88_1","doi-asserted-by":"crossref","unstructured":"HuangM YangG PatelD et al.ACH\u20102928: a novel highly potent HCV NS5A inhibitor with favorable preclinical characteristics. Poster presentations of the International Liver Congress 2011\u2014the 46th Annual Meeting of the European Association for the Study of the Liver (EASL) Berlin Germany 30 March\u20133 April2011.","DOI":"10.1016\/S0168-8278(11)61214-2"},{"key":"e_1_2_13_89_1","unstructured":"http:\/\/www.hepatitis\u2010central.com\/mt\/archives\/2011\/12\/initial_hep_c_d.html"},{"key":"e_1_2_13_90_1","doi-asserted-by":"crossref","unstructured":"DumasEO LawalA MenonRM et al.Pharmacokinetics safety and tolerability of the HCV NS5A inhibitor ABT\u2010267 following single and multiple doses in healthy adult volunteers. Poster presentations of the International Liver Congress 2011\u2014the 46th Annual Meeting of the European Association for the Study of the Liver (EASL) Berlin Germany 30 March\u20133 April2011.","DOI":"10.1016\/S0168-8278(11)61206-3"},{"key":"e_1_2_13_91_1","unstructured":"ColonnoR HuangQ HuangN et al.Comprehensive analysis shows conserved pathways to resistance across all major HCV genotypes for a panel of NS5A inhibitors. Poster presentations of the International Liver Congress 2011\u2014the 46th Annual Meeting of the European Association for the Study of the Liver (EASL) Berlin Germany 30 March\u20133 April2011."},{"key":"e_1_2_13_92_1","unstructured":"http:\/\/www.news\u2010medical.net\/news\/20100526\/Presidio\u2010Pharmaceuticals\u2010to\u2010advance\u2010PPI\u20101301\u2010inhibitor\u2010from\u2010HCV\u2010NS5A\u2010program\u2010into\u2010clinical\u2010development.aspx"},{"key":"e_1_2_13_93_1","doi-asserted-by":"crossref","unstructured":"GaneE FosterGR CianciaraJ et al.Antiviral activity pharmacokinetics and tolerability of AZD7295 a novel NS5A inhibitor in a placebo\u2010controlled multiple ascending dose study in HCV genotype 1 and 3 patients. Poster presentations of the International Liver Congress 2011\u2014the 46th Annual Meeting of the European Association for the Study of the Liver (EASL) Berlin Germany 30 March\u20133 April2011.","DOI":"10.1016\/S0168-8278(10)61194-4"},{"key":"e_1_2_13_94_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1797"},{"key":"e_1_2_13_95_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.161802"},{"key":"e_1_2_13_96_1","doi-asserted-by":"publisher","DOI":"10.1021\/jo201492m"},{"key":"e_1_2_13_97_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm100863x"},{"key":"e_1_2_13_98_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.05639-11"},{"key":"e_1_2_13_99_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2011.05.003"},{"key":"e_1_2_13_100_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2011.02710.x"},{"key":"e_1_2_13_101_1","first-page":"377A","article-title":"Once daily PSI\u20107977 plus RBV: pegylated interferon\u2010\u03b1 not required for complete rapid viral response in treatment\u2010na\u00efve patients with HCV GT2 or GT3. Abstracts of the 62th Annual Meeting of the American Association for the Study of Liver Diseases, San Francisco, CA, 6\u20139 November 2011","volume":"54","author":"Gane EJ","year":"2011","journal-title":"Hepatology"},{"issue":"1","key":"e_1_2_13_102_1","first-page":"abstract 50","article-title":"PSI\u20107977 with PEG\/RBV elicits rapid declines in HCV RNA in patients with HCV GT\u20104 and GT\u20106. HEP DART 2011, Kauai, Hawaii, 4\u20138 December 2011","volume":"7","author":"Hassanein T","year":"2011","journal-title":"Global Antiviral Journal"},{"key":"e_1_2_13_103_1","first-page":"706A","article-title":"High rapid virologic response (RVR) with PSI\u20107977 daily dosing plus PEG\u2010INF\/RBV in a 28\u2010day phase 2a trial. Presented at the 61st Annual Meeting of the American Association of the Study of Liver Diseases, Boston, MA, October 29\u2013November 2, 2010","volume":"52","author":"Lawitz E","year":"2010","journal-title":"Hepatology"},{"key":"e_1_2_13_104_1","first-page":"711A","article-title":"IL28B SNP geographical distribution and antiviral responses in a 28\u2010day phase 2A trial of PSI\u20107977 daily dosing plus PEG\u2010IFN\/RB. Presented at the 61st Annual Meeting of the American Association of the Study of Liver Diseases, Boston, MA, October 29\u2013November 2, 2010","volume":"52","author":"McHutchison JG","year":"2010","journal-title":"Hepatology"},{"key":"e_1_2_13_105_1","unstructured":"GaneE StedmanC HylandR et al.Once daily GS\u20107977 plus ribavirin in HCV genotypes 1\u20133: the ELECTRON trial. Poster presentations of the International Liver Congress 2012\u2014the 47th Annual Meeting of the European Association for the Study of the Liver (EASL) Barcelona Spain 18\u201322 April2012 #1113."},{"key":"e_1_2_13_106_1","unstructured":"KowdleyK LawitzE CrespoI et al.GS\u20107977\u2009+\u2009PEG\/RBV in HCV genotype 1: the ATOMIC trial. An end to response\u2010guided therapy?Poster presentations of the International Liver Congress 2012\u2014the 47th Annual Meeting of the European Association for the Study of the Liver (EASL) Barcelona Spain 18\u201322 April2012."},{"key":"e_1_2_13_107_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2010.06.094"},{"key":"e_1_2_13_108_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01335-10"},{"key":"e_1_2_13_109_1","unstructured":"http:\/\/www.natap.org\/2011\/HCV\/112911_01.htm"},{"key":"e_1_2_13_110_1","unstructured":"http:\/\/www.cardiff.ac.uk\/phrmy\/newsandevents\/news\/mcguigan\u2010antihepatitis\u2010c\u2010drug\u2010inx189\u2010synergy\u2010with\u2010ribavirin.html"},{"key":"e_1_2_13_111_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2010.04.003"},{"key":"e_1_2_13_112_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2088"},{"key":"e_1_2_13_113_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24788"},{"key":"e_1_2_13_114_1","doi-asserted-by":"crossref","unstructured":"PockrosP JensenD TsaiN et al.First SVR data with the nucleoside analogue polymerase inhibitor mericitabine (RG7128) combined with peginterferon\/ribavirin in treatment\u2010na\u00efve HCV G1\/4 patients: interim analysis from the JUMP\u2010C trial. Oral presentations of the International Liver Congress 2010\u2014the 46th Annual Meeting of the European Association for the Study of the Liver (EASL) Berlin Germany 30 March\u20133 April2011. Abstract 421.","DOI":"10.1016\/S0168-8278(11)61361-5"},{"key":"e_1_2_13_115_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01101-10"},{"key":"e_1_2_13_116_1","unstructured":"http:\/\/www.aliosbiopharma.com\/news_room\/press_releases\/alios_biopharma_inc_and_versitech_ltd_announce_exclusive_agreement"},{"key":"e_1_2_13_117_1","unstructured":"http:\/\/hepatitiscnewdrugs.blogspot.com\/2011\/12\/initiation\u2010of\u2010als\u20102200als\u20102158\u2010in.html?spref=tw"},{"key":"e_1_2_13_118_1","doi-asserted-by":"crossref","unstructured":"http:\/\/www.hivandhepatitis.com\/hep_c\/news\/2011\/0628_2011_a.html","DOI":"10.1055\/s-0030-1260434"},{"key":"e_1_2_13_119_1","unstructured":"http:\/\/www.bionity.com\/en\/news\/133196\/medivir\u2010s\u2010tmc649128\u2010enters\u2010phase\u2010ib\u2010trial\u2010in\u2010patients\u2010chronically\u2010infected\u2010with\u2010genotype\u20101\u2010hepatitis\u2010c\u2010virus.html"},{"key":"e_1_2_13_120_1","unstructured":"http:\/\/www.natap.org\/2012\/HCV\/021612_01.htm"},{"key":"e_1_2_13_121_1","doi-asserted-by":"crossref","unstructured":"Rodriguez\u2010TorresM LawitzE ConwayB et al.Safety and antiviral activity of the HCV non\u2010nucleoside polymerase inhibitor VX\u2010222 in treatment\u2010na\u00efve genotype 1 HCV\u2010infected patients. Oral presentations of the International Liver Congress 2010\u2014the 45th Annual Meeting of the European Association for the Study of the Liver (EASL) Vienna Austria 14\u201318 April2010.","DOI":"10.1016\/S0168-8278(10)60033-5"},{"key":"e_1_2_13_122_1","unstructured":"WagnerR MaringC DonnerPL et al.Preclinical characterization of ABT\u2010072: a novel non\u2010nucleoside HCV polymerase inhibitor. Abstracts of the International Liver Congress 2009\u2014the 44th Annual Meeting of the European Association for the Study of the Liver (EASL) Copenhagen Denmark 22\u201326 April2009."},{"key":"e_1_2_13_123_1","doi-asserted-by":"crossref","unstructured":"DumasE AwniW CohenD et al.Pharmacokinetics of the HCV polymerase inhibitor ABT\u2010072 following single and multiple dosing in healthy adult volunteers. Abstracts of the International Liver Congress 2010\u2014the 45th Annual Meeting of the European Association for the Study of the Liver (EASL) Vienna Austria 14\u201318 April2010.","DOI":"10.1016\/S0168-8278(10)60749-0"},{"key":"e_1_2_13_124_1","first-page":"1044A","article-title":"BI 207127 is a potent HCV RNA polymerase inhibitor during 5\u2009days monotherapy in patients with chronic hepatitis C","volume":"50","author":"Larrey DG","year":"2009","journal-title":"Hepatology"},{"key":"e_1_2_13_125_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00307-11"},{"key":"e_1_2_13_126_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm8014537"},{"key":"e_1_2_13_127_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05438-11"},{"key":"e_1_2_13_128_1","first-page":"938","article-title":"Filibuvir, a non\u2010nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection","volume":"13","author":"Beaulieu PL","year":"2010","journal-title":"Drugs"},{"key":"e_1_2_13_129_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05611-11"},{"key":"e_1_2_13_130_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24342"},{"key":"e_1_2_13_131_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh319"},{"key":"e_1_2_13_132_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2009.09.045"},{"key":"e_1_2_13_133_1","unstructured":"http:\/\/www.natap.org\/2011\/HCV\/101411_01.htm"},{"key":"e_1_2_13_134_1","doi-asserted-by":"crossref","unstructured":"NicolasO BoivinI St\u2010DenisC BedardJ.Genotypic analysis of HCV NS5B variants selected from patients treated with VCH\u2010759 and viral load declines. Abstracts of the International Liver Congress 2008\u2014the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL) Milan Italy 23\u201327 April2008.","DOI":"10.1016\/S0168-8278(08)60846-6"},{"key":"e_1_2_13_135_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2009.03.015"},{"key":"e_1_2_13_136_1","unstructured":"ProulxL BourgaultB ChauretN LaroucheR TanguayM ThibertR.Results of a safety tolerability and pharmacokinetic phase I study of VCH\u2010916 a novel polymerase inhibitor for HCV following single ascending doses in healthy volunteers. Abstracts of the International Liver Congress 2008\u2014the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL) Milan Italy 23\u201327 April2008."},{"key":"e_1_2_13_137_1","doi-asserted-by":"crossref","unstructured":"ChauretN Chagnon\u2010LabelleC DialloM LaquerreJ PlanteS.Preclinical pharmacokinetic and ADME characterization of VCH\u2010916 a novel non\u2010nucleoside HCV NS5B polymerase inhibitor. Abstracts of the International Liver Congress 2008\u2014the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL) Milan Italy 23\u201327 April2008.","DOI":"10.1016\/S0168-8278(08)60847-8"},{"key":"e_1_2_13_138_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2011.03.031"},{"key":"e_1_2_13_139_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00990-10"},{"key":"e_1_2_13_140_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.08.051"},{"key":"e_1_2_13_141_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24744"},{"key":"e_1_2_13_142_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.04.018"},{"key":"e_1_2_13_143_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61384-0"},{"key":"e_1_2_13_144_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61497-3"},{"key":"e_1_2_13_145_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24724"},{"key":"e_1_2_13_146_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104430"},{"key":"e_1_2_13_147_1","unstructured":"http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01434498"},{"key":"e_1_2_13_148_1","unstructured":"http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01482390"},{"key":"e_1_2_13_149_1","unstructured":"http:\/\/www.hivandhepatitis.com\/hcv\u2010treatment\/experimental\u2010hcv\u2010drugs\/3397\u2010merck\u2010and\u2010roche\u2010to\u2010collaborate\u2010on\u2010combination\u2010regimens\u2010for\u2010hepatitis\u2010c"},{"key":"e_1_2_13_150_1","unstructured":"http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01483742"},{"key":"e_1_2_13_151_1","unstructured":"GaultierIA CohenDE DumasEO LarsenLM PodsadeckiTJ BernsteinB.12\u2010Week efficacy and safety of ABT\u2010072 or ABT\u2010333 with pegylated interferon\u2009+\u2009ribavirin following 3\u2010day monotherapy in genotype 1 HCV\u2010infected treatment\u2010na\u00efve subjects. Abstracts of the 21st Conference of the Asian Pacific Association for the Study of the Liver (APASL 2011) Bangkok Thailand 17\u201320 February2011."},{"key":"e_1_2_13_152_1","unstructured":"http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01464827"},{"key":"e_1_2_13_153_1","unstructured":"http:\/\/hepatitiscnewdrugs.blogspot.com\/2011\/11\/aasld\u2010incivek\u2010vx\u2010222\u2010interim\u2010data.html"},{"key":"e_1_2_13_154_1","doi-asserted-by":"publisher","DOI":"10.2741\/3450"},{"key":"e_1_2_13_155_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature07684"},{"key":"e_1_2_13_156_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22547"},{"key":"e_1_2_13_157_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.06.024"},{"key":"e_1_2_13_158_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2341"},{"key":"e_1_2_13_159_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0902693106"},{"key":"e_1_2_13_160_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02418-08"},{"key":"e_1_2_13_161_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2009.02.001"},{"key":"e_1_2_13_162_1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.09-131920"},{"key":"e_1_2_13_163_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-1074"},{"key":"e_1_2_13_164_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt.11.87"},{"key":"e_1_2_13_165_1","unstructured":"http:\/\/www.marketwire.com\/press\u2010release\/peregrine\u2010initiates\u2010randomized\u2010phase\u2010ii\u2010trial\u2010of\u2010bavituximab\u2010in\u2010chronic\u2010hepatitis\u2010c\u2010nasdaq\u2010pphm\u20101377628.htm"},{"key":"e_1_2_13_166_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1113329"},{"key":"e_1_2_13_167_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2006.01.005"},{"key":"e_1_2_13_168_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1178178"},{"key":"e_1_2_13_169_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1016606108"},{"key":"e_1_2_13_170_1","first-page":"1430A","article-title":"A randomized, double\u2010blind, placebo (PLB) controlled safety and anti\u2010viral proof of concept study of miravirsen (MIR), an oligonucleotide targeting miR\u2010122, in treatment na\u00efve patients with genotype 1 (GT1) chronic HCV infection. Annual Meeting of the American Association for the Study of Liver Diseases, San Francisco, CA, 6\u20139 November 2011","volume":"54","author":"Janssen HL","year":"2011","journal-title":"Hepatology"},{"key":"e_1_2_13_171_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2005.05.014"},{"key":"e_1_2_13_172_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02614-07"},{"key":"e_1_2_13_173_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23281"},{"key":"e_1_2_13_174_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.01.041"},{"key":"e_1_2_13_175_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22835"},{"key":"e_1_2_13_176_1","first-page":"237","article-title":"Arrest all accessories\u2014inhibition of hepatitis C virus by compounds that target host factors","volume":"12","author":"Hahn T","year":"2011","journal-title":"Discovery Medicine"},{"key":"e_1_2_13_177_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01236-09"},{"key":"e_1_2_13_178_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0013687"},{"key":"e_1_2_13_179_1","doi-asserted-by":"publisher","DOI":"10.1021\/bi1003266"},{"key":"e_1_2_13_180_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25514"},{"key":"e_1_2_13_181_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.06641-11"},{"issue":"1","key":"e_1_2_13_182_1","first-page":"abstract 47","article-title":"Alisporivir plus pegIFN\u03b12a\/ribavirin treatment for chronic hepatitis C genotype (GT) 1 treatment na\u00efve patients shows superior sustained virologic response irrespective of IL28B genotype and high barrier to resistance. HEP DART 2011, Kauai, Hawaii, 4\u20138 December 2011","volume":"7","author":"Flisiak R","year":"2011","journal-title":"Global Antiviral Journal"},{"key":"e_1_2_13_183_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2012.658641"},{"key":"e_1_2_13_184_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2010.217323"},{"key":"e_1_2_13_185_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.60"},{"key":"e_1_2_13_186_1","unstructured":"TumasD ZhengX LuB et al.Preclinical characterization of GS\u20109620 a potent and selective oral TLR7 agonist. Poster presentations of the International Liver Congress 2011\u2014the 46th Annual Meeting of the European Association for the Study of the Liver (EASL) Berlin Germany 30 March\u20133 April2011."},{"key":"e_1_2_13_187_1","doi-asserted-by":"crossref","unstructured":"LopatinU WolfgangG KimberlinR et al.A phase\u2010I randomized double\u2010blind placebo\u2010controlled study to evaluate the safety tolerability pharmacokinetics and pharmacodynamics of single escalating oral doses of GS\u20109620 in healthy subjects. Poster presentations of the International Liver Congress 2011\u2014the 46th Annual Meeting of the European Association for the Study of the Liver (EASL) Berlin Germany 30 March\u20133 April2011.","DOI":"10.1016\/S0168-8278(11)60739-3"},{"key":"e_1_2_13_188_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.1490"},{"key":"e_1_2_13_189_1","doi-asserted-by":"publisher","DOI":"10.1086\/653080"},{"key":"e_1_2_13_190_1","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.624"},{"key":"e_1_2_13_191_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2008.10.010"},{"key":"e_1_2_13_192_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2424"}],"container-title":["Reviews in Medical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Frmv.1727","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/rmv.1727","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T04:16:04Z","timestamp":1697429764000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/rmv.1727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,30]]},"references-count":191,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["10.1002\/rmv.1727"],"URL":"https:\/\/doi.org\/10.1002\/rmv.1727","archive":["Portico"],"relation":{},"ISSN":["1052-9276","1099-1654"],"issn-type":[{"value":"1052-9276","type":"print"},{"value":"1099-1654","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8,30]]}}}